Drugs / Bromelains
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05258682 | May → Sep 2022 | COVID-19, acute respiratory distress syndrome, pneumonia | Mucpharm Pty Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bromelains | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05258682 ↗ |
| Route | Inhaled | “via inhalation using an approved vibrating mesh nebuliser (Aerogen Pro)” NCT05258682 ↗ |